The VELscope Vx from LED Medical Diagnostics, parent company of LED Dental, is currently involved in a phase III study designed to determine if fluorescence visualization-guided surgery can increase recurrence-free survival in oral cancer patients.
The study is sponsored by the University of British Columbia in collaboration with the Terry Fox Research Institute and the British Columbia Cancer Agency.
Previous research has shown that direct fluorescence visualization tools can effectively "identify clinically visible or occult premalignant and malignant lesions that are associated with lesions at risk with high-grade histology and high-risk molecular change," the company noted in a press release.
The study is designed to explore the efficacy of using the VELscope Vx for lesion excision and also the resultant effect on long-term recurrence rates, according to Peter Whitehead, LED Medical Diagnostics founder, president, and CEO.
